olaparib,bevacizumab
astrazeneca,roche,merck
['cohort i', 'olaparib', 'bev/', 'synergy', 'paola-1']
 the mpfs in the hrd+ cohort is favorable compared to the paola-1 arm of bev/olaparib in the same cohort, which suggests that we may finally be looking at the synergy between io/parpi declaring itself in a large randomized trial.
Medical Oncologist. Focus on #BreastCancer. Lifelong learner 📖 Travel ✈️ Hike 🥾 Cook 🥘 Workout 🏋️‍♀️ Video games 🎮 Tweets are my own opinions.